REFERENCES
1. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6.
2. Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol 2020;72:250-61.
3. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology 2021;73 Suppl 1:4-13.
4. Ge XY, Sun MC, Wang TY, et al. Analysis of risk factors of hepatocellular carcinoma and establishment of a clinical prognosis model. Front Oncol 2023;13:1067353.
5. Méndez-Sánchez N, Valencia-Rodriguez A, Vera-Barajas A, et al. The mechanism of dysbiosis in alcoholic liver disease leading to liver cancer. Hepatoma Res 2020;6:5.
6. Romeo I, Marascio N, Pavia G, et al. Structural modeling of new polymorphism clusters of HCV polymerase isolated from direct-acting antiviral naïve patients: focus on dasabuvir and setrobuvir binding affinity. ChemistrySelect 2018;3:6009-17.
7. Marascio N, Pavia G, Romeo I, et al. Real-life 3D therapy failure: analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling. J Med Virol 2018;90:1257-63.
8. Marascio N, Mazzitelli M, Pavia G, et al. Clinical, virological characteristics, and outcomes of treatment with sofosbuvir/ledipasvir in two pediatric patients infected by HCV genotype 4. Cells 2019;8:416.
9. Marascio N, Mazzitelli M, Scarlata GG, et al. HCV antibody prevalence and genotype evolution in a teaching hospital, Calabria region, Southern Italy over a decade (2008-2018). TOMICROJ 2020;14:84-90.
10. Wong GL, Hui VW, Yip TC, et al. Universal HBV vaccination dramatically reduces the prevalence of HBV infection and incidence of hepatocellular carcinoma. Aliment Pharmacol Ther 2022;56:869-77.
11. Masarone M, Federico A, Abenavoli L, Loguercio C, Persico M. Non alcoholic fatty liver: epidemiology and natural history. Rev Recent Clin Trials 2014;9:126-33.
12. Zhang P. Influence of Foods and Nutrition on the Gut Microbiome and Implications for Intestinal Health. Int J Mol Sci 2022;23:9588.
13. Abenavoli L, Scarlata GGM, Paravati MR, Boccuto L, Luzza F, Scarpellini E. Gut microbiota and liver transplantation: immune mechanisms behind the rejection. Biomedicines 2023;11:1792.
14. Gopalakrishnan V, Helmink BA, Spencer CN, Reuben A, Wargo JA. The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell 2018;33:570-80.
15. Abenavoli L, Montori M, Svegliati Baroni G, et al. Perspective on the role of gut microbiome in the treatment of hepatocellular carcinoma with immune checkpoint inhibitors. Medicina 2023;59:1427.
16. Maestri M, Santopaolo F, Pompili M, Gasbarrini A, Ponziani FR. Gut microbiota modulation in patients with non-alcoholic fatty liver disease: effects of current treatments and future strategies. Front Nutr 2023;10:1110536.
17. Tripathi A, Debelius J, Brenner DA, et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol 2018;15:397-411.
18. Wang Y, Pan CQ, Xing H. Advances in gut microbiota of viral hepatitis cirrhosis. Biomed Res Int 2019;2019:9726786.
19. Abenavoli L, Di Renzo L, Boccuto L, Alwardat N, Gratteri S, De Lorenzo A. Health benefits of Mediterranean diet in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2018;12:873-81.
20. Plaz Torres MC, Aghemo A, Lleo A, et al. Mediterranean diet and NAFLD: what we know and questions that still need to be answered. Nutrients 2019;11:2971.
21. Abenavoli L, Scarpellini E, Pellicano R, Fagoonee S, Larussa T, Luzza F. Mediterranean diet and probiotics supplementation to treat non-alcoholic fatty liver disease. Minerva Med 2020;111:526-8.
22. Abenavoli L, Procopio AC, Paravati MR, et al. Mediterranean diet: the beneficial effects of lycopene in non-alcoholic fatty liver disease. J Clin Med 2022;11:3477.
23. Zohoori F. Chapter 1: Nutrition and diet. In: Zohoori FV, Duckworth RM, editors. The Impact of Nutrition and Diet on Oral Health. S. Karger AG; 2020. pp. 1-13.
24. Rowland I, Gibson G, Heinken A, et al. Gut microbiota functions: metabolism of nutrients and other food components. Eur J Nutr 2018;57:1-24.
25. Ruiz-Margáin A, Román-Calleja BM, Moreno-Guillén P, et al. Nutritional therapy for hepatocellular carcinoma. World J Gastrointest Oncol 2021;13:1440-52.
26. Malmir H, Mahdavi FS, Ejtahed HS, et al. Junk food consumption and psychological distress in children and adolescents: a systematic review and meta-analysis. Nutr Neurosci 2023;26:807-27.
27. Bohara SS, Thapa K, Bhatt LD, Dhami SS, Wagle S. Determinants of junk food consumption among adolescents in Pokhara valley, Nepal. Front Nutr 2021;8:644650.
28. Hymel E, Vlock E, Fisher KW, Farazi PA. Differential progression of unhealthy diet-induced hepatocellular carcinoma in obese and non-obese mice. PLoS One 2022;17:e0272623.
29. Bojková B, Winklewski PJ, Wszedybyl-Winklewska M. Dietary fat and cancer-which is good, which is bad, and the body of evidence. Int J Mol Sci 2020;21:4114.
30. Masood W, Annamaraju P, Khan Suheb MZ, Uppaluri KR. Ketogenic diet. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499830/ [Last accessed on 23 Apr 2024].
31. Luo W, Zhang J, Xu D, et al. Low carbohydrate ketogenic diets reduce cardiovascular risk factor levels in obese or overweight patients with T2DM: a meta-analysis of randomized controlled trials. Front Nutr 2022;9:1092031.
32. Pietrzak D, Kasperek K, Rękawek P, Piątkowska-Chmiel I. The therapeutic role of ketogenic diet in neurological disorders. Nutrients 2022;14:1952.
33. Danan A, Westman EC, Saslow LR, Ede G. The ketogenic diet for refractory mental illness: a retrospective analysis of 31 inpatients. Front Psychiatry 2022;13:951376.
34. Landry MJ, Crimarco A, Perelman D, et al. Adherence to ketogenic and mediterranean study diets in a crossover trial: the keto-med randomized trial. Nutrients 2021;13:967.
35. Healy ME, Chow JD, Byrne FL, et al. Dietary effects on liver tumor burden in mice treated with the hepatocellular carcinogen diethylnitrosamine. J Hepatol 2015;62:599-606.
36. Huang D, Li T, Wang L, et al. Hepatocellular carcinoma redirects to ketolysis for progression under nutrition deprivation stress. Cell Res 2016;26:1112-30.
37. Byrne FL, Hargett SR, Lahiri S, et al. Serial MRI imaging reveals minimal impact of ketogenic diet on established liver tumor growth. Cancers 2018;10:312.
38. Motta J, Lobo L, Fabiola D. Ketogenic diet against liver tumor. Current Developments in Nutrition 2020;4:338.
39. Davis C, Bryan J, Hodgson J, Murphy K. Definition of the mediterranean diet; a literature review. Nutrients 2015;7:9139-53.
40. Merra G, Noce A, Marrone G, et al. Influence of mediterranean diet on human gut microbiota. Nutrients 2020;13:7.
41. Schwingshackl L, Morze J, Hoffmann G. Mediterranean diet and health status: active ingredients and pharmacological mechanisms. Br J Pharmacol 2020;177:1241-57.
42. Abenavoli L, Boccuto L, Federico A, et al. Diet and non-alcoholic fatty liver disease: the mediterranean way. Int J Environ Res Public Health 2019;16:3011.
43. Colica C, DE Lorenzo A, Abenavoli L. Mediterranean diet in liver steatosis: the role of polyphenols. Minerva Gastroenterol Dietol 2018;64:97-9.
44. Calabrò A, Procopio AC, Primerano F, et al. Beneficial effects of coffee in non-alcoholic fatty liver disease: a narrative review. Hepatoma Res 2020;6:69.
45. Turati F, Trichopoulos D, Polesel J, et al. Mediterranean diet and hepatocellular carcinoma. J Hepatol 2014;60:606-11.
46. Li WQ, Park Y, McGlynn KA, et al. Index-based dietary patterns and risk of incident hepatocellular carcinoma and mortality from chronic liver disease in a prospective study. Hepatology 2014;60:588-97.
47. Ma Y, Yang W, Simon TG, et al. Dietary patterns and risk of hepatocellular carcinoma among U.S. men and women. Hepatology 2019;70:577-86.
48. Bogumil D, Park SY, Le Marchand L, et al. High-quality diets are associated with reduced risk of hepatocellular carcinoma and chronic liver disease: the multiethnic cohort. Hepatol Commun 2019;3:437-47.
49. Mentella MC, Scaldaferri F, Ricci C, Gasbarrini A, Miggiano GAD. Cancer and mediterranean diet: a review. Nutrients 2019;11:2059.
50. Procopio AC, Paravati MR, Scarlata GGM, et al. Is the mediterranean diet a good preventive measure for NASH? Hepatoma Res 2024;10:9.
51. Liu K, Verset G, Trepo E, Seth D. Genetics of alcohol-related hepatocellular carcinoma - its role in risk prediction. Hepatoma Res 2020;6:42.
52. Teschke R. Hepatocellular carcinoma in alcoholic liver disease: mechanistic considerations and clinical facts. Hepatoma Res 2019;5:40.
53. Chen P, Li Y, Dai Y, et al. Advances in the pathogenesis of metabolic liver disease-related hepatocellular carcinoma. J Hepatocell Carcinoma 2024;11:581-94.
54. Puoti C. New insights on hepatocellular carcinoma: epidemiology and clinical aspects. Hepatoma Res 2018;4:57.
55. Geh D, Anstee QM, Reeves HL. NAFLD-associated HCC: progress and opportunities. J Hepatocell Carcinoma 2021;8:223-39.
56. Hou K, Wu ZX, Chen XY, et al. Microbiota in health and diseases. Signal Transduct Target Ther 2022;7:135.
57. Ghosh SS, Wang J, Yannie PJ, Ghosh S. Intestinal barrier dysfunction, LPS translocation, and disease development. J Endocr Soc 2020;4:bvz039.
58. Temraz S, Nassar F, Kreidieh F, Mukherji D, Shamseddine A, Nasr R. Hepatocellular carcinoma immunotherapy and the potential influence of gut microbiome. Int J Mol Sci 2021;22:7800.
59. Abenavoli L, Scarlata GGM, Scarpellini E, et al. Metabolic-dysfunction-associated fatty liver disease and gut microbiota: from fatty liver to dysmetabolic syndrome. Medicina 2023;59:594.
60. Marascio N, De Caro C, Quirino A, et al. The role of the microbiota gut-liver axis during HCV chronic infection: a schematic overview. J Clin Med 2022;11:5936.
61. Ponziani FR, Bhoori S, Castelli C, et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology 2019;69:107-20.
62. Effenberger M, Waschina S, Bronowski C, et al. A gut bacterial signature in blood and liver tissue characterizes cirrhosis and hepatocellular carcinoma. Hepatol Commun 2023;7:e00182.
63. Ma J, Li J, Jin C, et al. Association of gut microbiome and primary liver cancer: a two-sample mendelian randomization and case-control study. Liver Int 2023;43:221-33.
64. Yang S, Dai H, Lu Y, Li R, Gao C, Pan S. Trimethylamine N-oxide promotes cell proliferation and angiogenesis in colorectal cancer. J Immunol Res 2022;2022:7043856.
65. Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015;350:1079-84.
66. Ayers M, Lunceford J, Nebozhyn M, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 2017;127:2930-40.
67. Tanoue T, Morita S, Plichta DR, et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature 2019;565:600-5.
68. Zheng Y, Wang T, Tu X, et al. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J Immunother Cancer 2019;7:193.
69. Lee PC, Wu CJ, Hung YW, et al. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer 2022;10:e004779.
70. Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013;499:97-101.
71. Luo W, Guo S, Zhou Y, et al. Hepatocellular carcinoma: how the gut microbiota contributes to pathogenesis, diagnosis, and therapy. Front Microbiol 2022;13:873160.
72. Ganesan R, Yoon SJ, Suk KT. Microbiome and metabolomics in liver cancer: scientific technology. Int J Mol Sci 2022;24:537.
73. Wan MLY, El-Nezami H. Targeting gut microbiota in hepatocellular carcinoma: probiotics as a novel therapy. Hepatobiliary Surg Nutr 2018;7:11-20.
74. Ma C, Han M, Heinrich B, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science 2018;360:eaan5931.
75. Yamada S, Takashina Y, Watanabe M, et al. Bile acid metabolism regulated by the gut microbiota promotes non-alcoholic steatohepatitis-associated hepatocellular carcinoma in mice. Oncotarget 2018;9:9925-39.
76. Van Rooyen DM, Larter CZ, Haigh WG, et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology 2011;141:1393-403, 1403.e1-5.
77. Liu D, Wong CC, Fu L, et al. Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target. Sci Transl Med 2018;10:eaap9840.
78. McGettigan B, McMahan R, Orlicky D, et al. Dietary lipids differentially shape nonalcoholic steatohepatitis progression and the transcriptome of kupffer cells and infiltrating macrophages. Hepatology 2019;70:67-83.
79. Zhang X, Coker OO, Chu ES, et al. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut 2021;70:761-74.
80. Zhou F, Sun X. Cholesterol metabolism: a double-edged sword in hepatocellular carcinoma. Front Cell Dev Biol 2021;9:762828.
81. Zhao S, Jang C, Liu J, et al. Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate. Nature 2020;579:586-91.
82. Pan Y, Zhang X. Diet and gut microbiome in fatty liver and its associated liver cancer. J Gastroenterol Hepatol 2022;37:7-14.
83. Moussa I, Day RS, Li R, et al. Association of dietary fat intake and hepatocellular carcinoma among US adults. Cancer Med 2021;10:7308-19.
84. Chang Y, Liu Q, Zhou Z, et al. Can statin treatment reduce the risk of hepatocellular carcinoma? A systematic review and meta-analysis. Technol Cancer Res Treat 2020;19:1533033820934881.
85. Russo A, Serapide F, Quirino A, et al. Microbiological and clinical findings of SARS-CoV-2 infection after 2 years of pandemic: from lung to gut microbiota. Diagnostics 2022;12:2143.
86. Abenavoli L, Scarpellini E, Paravati MR, et al. Gut microbiota and critically ill patients: immunity and its modulation via probiotics and immunonutrition. Nutrients 2023;15:3569.
87. Marascio N, Scarlata GGM, Romeo F, et al. The role of gut microbiota in the clinical outcome of septic patients: state of the art and future perspectives. Int J Mol Sci 2023;24:9307.
88. Claesson MJ, Clooney AG, O'Toole PW. A clinician’s guide to microbiome analysis. Nat Rev Gastroenterol Hepatol 2017;14:585-95.
89. Odrzywolek K, Karwowska Z, Majta J, Byrski A, Milanowska-Zabel K, Kosciolek T. Deep embeddings to comprehend and visualize microbiome protein space. Sci Rep 2022;12:10332.
90. Cammarota G, Ianiro G, Ahern A, et al. Gut microbiome, big data and machine learning to promote precision medicine for cancer. Nat Rev Gastroenterol Hepatol 2020;17:635-48.
91. Sundh J, Tanash H, Arian R, et al. Advanced dental cleaning is associated with reduced risk of COPD exacerbations - a randomized controlled trial. Int J Chron Obstruct Pulmon Dis 2021;16:3203-15.
92. Wirbel J, Zych K, Essex M, et al. Microbiome meta-analysis and cross-disease comparison enabled by the SIAMCAT machine learning toolbox. Genome Biol 2021;22:93.
